Biogen announces plans to start their global phase 3 trial of Omaveloxolone in children aged 2-15, with sites in the UK
Biogen have shared their plan to initiate their BRAVE study, a global phase 3 trial of Omaveloxolone (SKYCLARYS®) in children aged 2-15 years. The trial will study the effects and […]